These products may not be used for compounding in any circumstance. It is against this backdrop that the FDA issued an April 27, 2023, letter to the National Association Boards of Pharmacy (NABP), stating that the API in Wegovy and Ozempic is semaglutide in its base form
Hambright WS, Fonseca RS, Chen L, Na R, Ran Q (2017) Ablation of ferroptosis regulator glutathione peroxidase 4 in forebrain neurons promotes cognitive impairment and neurodegeneration
FDA is aware of compounded semaglutide products that are being marketed for weight loss, the agency said
Members say: GLP-1 Companion: Ask about how we support every step of the GLP-1 journey, from prior authorization, to safe and successful use, to lasting weight health without medication